trial · primary record
Bispecific antibody-based combined with CAR-T cell therapy
B-cell Non-Hodgkin Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 53 |
| Primary completion | 2027-04-30 |
| Primary endpoint | Incidence rate and severity of adverse events (AE) of patients treated with bispecific antibody combined with CD19-CAR-T cells in B-NHL.（Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events.） |
| Registry ID | NCT06464185 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:45.708Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06464185
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.